View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsByotrol 배당 및 자사주 매입배당 기준 점검 0/6Byotrol 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-6.5%자사주 매입 수익률총 주주 수익률-6.5%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 28Byotrol plc, Annual General Meeting, Apr 22, 2024Byotrol plc, Annual General Meeting, Apr 22, 2024, at 10:00 Coordinated Universal Time. Location: Riverbank House, 2 Swan Lane, - London United KingdomReported Earnings • Dec 09First half 2024 earnings released: UK£0.002 loss per share (vs UK£0.001 loss in 1H 2023)First half 2024 results: UK£0.002 loss per share (further deteriorated from UK£0.001 loss in 1H 2023). Revenue: UK£2.02m (down 9.4% from 1H 2023). Net loss: UK£742.0k (loss widened 28% from 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 25 percentage points per year, which is a significant difference in performance.New Risk • Nov 14New major risk - Revenue and earnings growthEarnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (153% average daily change). Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (€3.39m market cap, or US$3.68m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£1.5m). Currently unprofitable and not forecast to become profitable next year (UK£800k net loss next year).공시 • Nov 14Byotrol plc Provides Sales Guidance for the Full Year Ending March 31, 2024Byotrol plc provided sales guidance for the full year ending March 31, 2024. For the year, the company expects product sales of approximately £3.9 million, which shows modest growth on £3.7 million in the previous year on a like-for-like basis (excluding discontinued items). Including discontinued items, prior year product sales were £4.3 million.공시 • Sep 27Byotrol plc Announces Chief Executive Officer ChangesByotrol plc announced that Vivan Pinto, CEO of the Company, has stepped down as CEO and left the Company to pursue other opportunities. David Traynor formerly Byotrol CEO 2013 - 2022 has kindly agreed to act as interim CEO until a suitable replacement for Vivan is appointed.공시 • Sep 08Byotrol plc Announces the Appointment of Ashley Head to the Board as an Independent Non-Executive Director, with Effect from 13 September 2023Byotrol plc announced the appointment of Ashley Head to the Board as an independent Non-Executive Director, with effect from AGM on 13 September 2023. Ashley began his career with Chase Manhattan Bank, where he rose through the ranks of technology and online banking. He then joined MasterCard, where he became responsible for the African region of the group. After recognising the opportunities within eCommerce Ashley founded Proc Cyber, growing the business to a valuation of over £60 million in three years and then merging with Datacash in 2006 where he assumed the role of Chairman. Under Ashley's leadership, Datacash grew to a market leading position with MasterCard purchasing the company in 2010. Ashley continues to lead a vibrant portfolio career and currently serves as Chairman of The AI Corporation, MySense Group and Champagne Piaff in addition to other director positions. He is also a trustee for the National Emergency Trust, Epsom College and Stonegate Foundation.공시 • Aug 30Byotrol plc Announces Launch of CHEMGENE MEDLAB into Human HealthcareByotrol plc announced the launch into human healthcare of its next-generation surface disinfection chemistry, branded CHEMGENE MEDLAB. The CHEMGENE brand, previously marketed by Medimark Scientific Ltd. and acquired by Byotrol in 2018, enjoys a long-standing reputation as a trusted choice for disinfecting surfaces and equipment across emergency services, laboratories, and human health organisations. This new formulation is designed for market-leading, broad-spectrum efficacy, low toxicity and regulatory approval across the UK and EU under the increasingly stringent biocidal regulations. CHEMGENE MEDLAB Multi-Surface Disinfectants are very effective against bacteria, yeasts, fungi, and viruses, with specifically tailored efficacy against: The ESKAPE group of bacteria, targeted in healthcare environments for their multi-drug resistance, and virulence. Critical viruses, including Norovirus, Adenovirus, and the Vaccinia virus-the accepted surrogate for enveloped viruses such as Coronavirus, HIV, Hepatitis B & C, and Herpes Simplex virus. Emerging fungus Candida auris, known for its global health threat due to multi-drug resistance and ease of transmission within healthcare settings. CHEMGENE MEDLAB Multi-Surface Disinfectants are supported by rigorous microbiological testing to the latest European efficacy test methodologies, including stringent medical standards that simulate high soil conditions akin to the presence of blood and other organic fluids during disinfection.New Risk • Aug 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.74m (US$9.46m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (37% average weekly change). Market cap is less than US$10m (€8.74m market cap, or US$9.46m). Minor Risk Less than 1 year of cash runway based on current free cash flow (-UK£1.5m).Reported Earnings • Jul 31Full year 2023 earnings released: UK£0.26 loss per share (vs UK£0.003 loss in FY 2022)Full year 2023 results: UK£0.26 loss per share (further deteriorated from UK£0.003 loss in FY 2022). Revenue: UK£4.59m (down 27% from FY 2022). Net loss: UK£1.69m (loss widened 26% from FY 2022). Revenue is expected to decline by 20% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 2.2%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 143 percentage points per year, which is a significant difference in performance.New Risk • Jun 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (43% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£471k net loss next year). Market cap is less than US$100m (€10.1m market cap, or US$10.9m).New Risk • Jun 12New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£1.8m Forecast net loss in 1 year: UK£471k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (43% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£471k net loss next year). Market cap is less than US$100m (€10.1m market cap, or US$10.8m).공시 • May 25Byotrol plc Announces EPA Approval for Long-Lasting Performance Against Virucidal ClaimsByotrol Plc announced that the US Environmental Protection Agency ("EPA") has formally approved long-lasting virucidal claims for its proprietary 24-hour germ-kill surface sanitizer Byotrol 24 (EPA Reg. Number 83614-1). This approval was received by the Company after close of business, on 22 May 2023. The Directors believe that this is the first product to receive such EPA approval and means that Byotrol24 and its sub brands will now be able to offer unique and highly relevant claims and performance characteristics to US consumers and businesses. This includes being able to claim efficacy against certain current and emerging viral pathogens including influenza, coronavirus and norovirus (via the commonly accepted surrogate feline calicivirus). The Company continues to advance alliances and commercial opportunities in the US, including with a previously announced, well-known sub-licensee in the US institutional market, which is continuing to prepare a market launch with the new product claims at the forefront of its marketing strategy.Reported Earnings • Dec 13First half 2023 earnings released: UK£0.13 loss per share (vs UK£0 in 1H 2022)First half 2023 results: UK£0.13 loss per share (further deteriorated from UK£0 in 1H 2022). Revenue: UK£2.23m (down 30% from 1H 2022). Net loss: UK£579.0k (loss widened 391% from 1H 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 117 percentage points per year, which is a significant difference in performance.공시 • Nov 22Byotrol plc Announces Management ChangesByotrol plc announced the following long-planned board changes. John Langlands, Non-Executive Chairman since February 2017, has notified the Board of his retirement from business and to step-down as Chairman and as a Director of Byotrol. John originally only intended to serve as Chairman of Byotrol for five years, but has remained slightly longer to guide the Company through this year's AGM. John will initially remain as a Non Executive Director to aid the leadership transition, but will then retire as a Director on 31 January 2023, having completed 6 years of service. David Traynor, Chief Executive Officer since October 2013 is moving to Executive Chairman, with immediate effect. In addition to his responsibilities as Chairman, David will now focus on securing and developing intellectual property agreements and commercial alliances for the Company. Vivan Pinto, currently Byotrol's Chief Growth Officer, and formerly VP and Area MD at Johnson and Johnson Consumer Health, is being promoted to Chief Executive Officer and joins the Board as an Executive Director with immediate effect. He will now assume formal responsibility for the day-to-day sales and operations of the Company, working closely with Chris Sedwell, Executive Director and Chief Financial Officer.Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CFO & Director Chris Sedwell was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 20Full year 2022 earnings released: UK£0.003 loss per share (vs UK£0.002 profit in FY 2021)Full year 2022 results: UK£0.003 loss per share (down from UK£0.002 profit in FY 2021). Revenue: UK£6.33m (down 44% from FY 2021). Net loss: UK£1.35m (down 238% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.Reported Earnings • Sep 01Full year 2022 earnings released: UK£0.003 loss per share (vs UK£0.002 profit in FY 2021)Full year 2022 results: UK£0.003 loss per share (down from UK£0.002 profit in FY 2021). Revenue: UK£6.33m (down 44% from FY 2021). Net loss: UK£1.35m (down 238% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.공시 • Sep 01Byotrol plc, Annual General Meeting, Sep 22, 2022Byotrol plc, Annual General Meeting, Sep 22, 2022, at 10:00 Coordinated Universal Time.공시 • Jul 29Byotrol plc announced that it has received £1 million in fundingByotrol plc announced a private placement of convertible loan notes for gross proceeds of £1,000,000 on July 28, 2022. The transaction included participation from new investors C Sedwell, Chief Financial Officer for £50,000, S Gogarty, Non-Executive Director for £100,000 and returning investors D Traynor, Chief Executive Officer for £50,000, V Pinto, Chief Growth Officer for £100,000, and T Francis, Non-Executive Director for £200,000. The loan notes have a term of five years, are senior in ranking, unsecured and convertible at investors' option into ordinary shares in the capital of the company at a price of £0.0325 (3.25 pence) per ordinary share, representing a 30% premium to the mid-price of the company's share price at close of business on 26 July 2022. The loan notes carry a coupon of 9% per annum, payable quarterly in arrears.공시 • Jul 11Byotrol plc Provides Earnings Guidance for the Full Year Ended March 31, 2022Byotrol plc provided earnings guidance for the full year ended March 31, 2022. For the period, the company expected Sales of £6.3 million, comprising £5.2 million from product sales and £1.1 million from IP sales and royalties.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CFO & Director Chris Sedwell was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 21Full year 2021 earnings released: EPS UK£0.002 (vs UK£0.001 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£11.2m (up 85% from FY 2020). Net income: UK£979.0k (up 193% from FY 2020). Profit margin: 8.7% (up from 5.5% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.공시 • Apr 24Byotrol plc Provides Earnings Guidance for the Full Year Ended March 31, 2021Byotrol plc provided earnings guidance for the full year ended March 31, 2021. For the period, the company expected turnover to be in excess of £11 million compared to £6.1 million a year ago.공시 • Feb 27Byotrol plc Announces That It Has Developed and Externally Validated A New Test for Determining Whether Cleaning and Sanitising ProductsByotrol plc announced that it has developed and externally validated a new test for determining whether cleaning and sanitising products have long-lasting efficacy against viruses in real-life use. This new test determines whether sanitising and cleaning products offer any long-lasting protection against COVID-19. Byotrol is now standing behind product efficacy claims supporting infection control products that offer 24-hour protection against viruses and bacteria in real-life conditions, where surfaces are frequently touched. The Company believes that this new test could help minimise the spread of the virus when used in conjunction with the cleaning and sanitising of shops, schools and offices when they reopen. The company has developed the new test in response to an increasing number of products claiming long-lasting efficacy against coronavirus, based on laboratory conditions which ignore the constant abrasion of surfaces in real-life environments (and which would then make many products ineffective). The company developed the industry standard test for long-lasting efficacy in real-life against bacteria and yeast in 2014 with the help of independent industry experts. The test, named PAS 2424:2014, was approved by the British Standards Institute (BSI) and is the only British standard to prove the efficacy of a disinfectant product over 24 hours. The PAS 2424:2014 test is currently being reviewed by the CEN Committee for approval as a new European EN test standard. This new test for viruses simulates 'real-life' conditions by creating frequent abrasions on surfaces after products have been applied, to replicate frequent touching of surfaces throughout the day. The surfaces are then tested to see whether the product is still present and killing viruses. The test is limited to 24 hours, to ensure that the result is attributed to the efficacy of the product, not the length of time the virus has been left to dry out on a surface, which could result in a false positive. The company plans to gain approval from the BSI again, to make this new test the British standard for proving the long-lasting efficacy of disinfectants against viruses. The application of this test could help businesses and consumers select products which are proven to be effective in a variety of public spaces where surfaces are frequently touched, genuinely promoting public health.Reported Earnings • Dec 10First half 2021 earnings released: EPS UK£0.002The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: UK£6.67m (up 207% from 1H 2020). Net income: UK£1.01m (up UK£1.64m from 1H 2020). Profit margin: 15% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue.공시 • Nov 14Byotrol plc Announces Retirement of Till Medinger from the BoardByotrol plc now confirm the formal retirement of Dr. Till Medinger from the Board.Reported Earnings • Oct 14Full year earnings released - EPS €0.00077Over the last 12 months the company has reported total profits of UK£334.0k, down 5.6% from the prior year. Total revenue was UK£6.07m over the last 12 months, up 7.1% from the prior year. Profit margins were 5.5%, which is in line with last year.Analyst Estimate Surprise Post Earnings • Oct 14Annual earnings released: Revenue beats expectationsAnnual revenue exceeded analyst estimates by 1.2% at UK£6.07m. Revenue is forecast to grow 89% over the next year, while the growth in Chemicals industry in Germany is expected to stay flat.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 B7Y 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: B7Y 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Byotrol 배당 수익률 vs 시장B7Y의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (B7Y)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.5%업계 평균 (Chemicals)3.8%분석가 예측 (B7Y) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 B7Y 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 B7Y 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 B7Y 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: B7Y 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/06/05 01:24종가2024/04/29 00:00수익2023/09/30연간 수익2023/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Byotrol plc는 4명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관David BuxtonCavendishAndrew Murray DarleyCavendishStephen McGarryCavendish1명의 분석가 더 보기
공시 • Mar 28Byotrol plc, Annual General Meeting, Apr 22, 2024Byotrol plc, Annual General Meeting, Apr 22, 2024, at 10:00 Coordinated Universal Time. Location: Riverbank House, 2 Swan Lane, - London United Kingdom
Reported Earnings • Dec 09First half 2024 earnings released: UK£0.002 loss per share (vs UK£0.001 loss in 1H 2023)First half 2024 results: UK£0.002 loss per share (further deteriorated from UK£0.001 loss in 1H 2023). Revenue: UK£2.02m (down 9.4% from 1H 2023). Net loss: UK£742.0k (loss widened 28% from 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 25 percentage points per year, which is a significant difference in performance.
New Risk • Nov 14New major risk - Revenue and earnings growthEarnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (153% average daily change). Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (€3.39m market cap, or US$3.68m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£1.5m). Currently unprofitable and not forecast to become profitable next year (UK£800k net loss next year).
공시 • Nov 14Byotrol plc Provides Sales Guidance for the Full Year Ending March 31, 2024Byotrol plc provided sales guidance for the full year ending March 31, 2024. For the year, the company expects product sales of approximately £3.9 million, which shows modest growth on £3.7 million in the previous year on a like-for-like basis (excluding discontinued items). Including discontinued items, prior year product sales were £4.3 million.
공시 • Sep 27Byotrol plc Announces Chief Executive Officer ChangesByotrol plc announced that Vivan Pinto, CEO of the Company, has stepped down as CEO and left the Company to pursue other opportunities. David Traynor formerly Byotrol CEO 2013 - 2022 has kindly agreed to act as interim CEO until a suitable replacement for Vivan is appointed.
공시 • Sep 08Byotrol plc Announces the Appointment of Ashley Head to the Board as an Independent Non-Executive Director, with Effect from 13 September 2023Byotrol plc announced the appointment of Ashley Head to the Board as an independent Non-Executive Director, with effect from AGM on 13 September 2023. Ashley began his career with Chase Manhattan Bank, where he rose through the ranks of technology and online banking. He then joined MasterCard, where he became responsible for the African region of the group. After recognising the opportunities within eCommerce Ashley founded Proc Cyber, growing the business to a valuation of over £60 million in three years and then merging with Datacash in 2006 where he assumed the role of Chairman. Under Ashley's leadership, Datacash grew to a market leading position with MasterCard purchasing the company in 2010. Ashley continues to lead a vibrant portfolio career and currently serves as Chairman of The AI Corporation, MySense Group and Champagne Piaff in addition to other director positions. He is also a trustee for the National Emergency Trust, Epsom College and Stonegate Foundation.
공시 • Aug 30Byotrol plc Announces Launch of CHEMGENE MEDLAB into Human HealthcareByotrol plc announced the launch into human healthcare of its next-generation surface disinfection chemistry, branded CHEMGENE MEDLAB. The CHEMGENE brand, previously marketed by Medimark Scientific Ltd. and acquired by Byotrol in 2018, enjoys a long-standing reputation as a trusted choice for disinfecting surfaces and equipment across emergency services, laboratories, and human health organisations. This new formulation is designed for market-leading, broad-spectrum efficacy, low toxicity and regulatory approval across the UK and EU under the increasingly stringent biocidal regulations. CHEMGENE MEDLAB Multi-Surface Disinfectants are very effective against bacteria, yeasts, fungi, and viruses, with specifically tailored efficacy against: The ESKAPE group of bacteria, targeted in healthcare environments for their multi-drug resistance, and virulence. Critical viruses, including Norovirus, Adenovirus, and the Vaccinia virus-the accepted surrogate for enveloped viruses such as Coronavirus, HIV, Hepatitis B & C, and Herpes Simplex virus. Emerging fungus Candida auris, known for its global health threat due to multi-drug resistance and ease of transmission within healthcare settings. CHEMGENE MEDLAB Multi-Surface Disinfectants are supported by rigorous microbiological testing to the latest European efficacy test methodologies, including stringent medical standards that simulate high soil conditions akin to the presence of blood and other organic fluids during disinfection.
New Risk • Aug 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.74m (US$9.46m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (37% average weekly change). Market cap is less than US$10m (€8.74m market cap, or US$9.46m). Minor Risk Less than 1 year of cash runway based on current free cash flow (-UK£1.5m).
Reported Earnings • Jul 31Full year 2023 earnings released: UK£0.26 loss per share (vs UK£0.003 loss in FY 2022)Full year 2023 results: UK£0.26 loss per share (further deteriorated from UK£0.003 loss in FY 2022). Revenue: UK£4.59m (down 27% from FY 2022). Net loss: UK£1.69m (loss widened 26% from FY 2022). Revenue is expected to decline by 20% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 2.2%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 143 percentage points per year, which is a significant difference in performance.
New Risk • Jun 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (43% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£471k net loss next year). Market cap is less than US$100m (€10.1m market cap, or US$10.9m).
New Risk • Jun 12New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£1.8m Forecast net loss in 1 year: UK£471k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (43% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£471k net loss next year). Market cap is less than US$100m (€10.1m market cap, or US$10.8m).
공시 • May 25Byotrol plc Announces EPA Approval for Long-Lasting Performance Against Virucidal ClaimsByotrol Plc announced that the US Environmental Protection Agency ("EPA") has formally approved long-lasting virucidal claims for its proprietary 24-hour germ-kill surface sanitizer Byotrol 24 (EPA Reg. Number 83614-1). This approval was received by the Company after close of business, on 22 May 2023. The Directors believe that this is the first product to receive such EPA approval and means that Byotrol24 and its sub brands will now be able to offer unique and highly relevant claims and performance characteristics to US consumers and businesses. This includes being able to claim efficacy against certain current and emerging viral pathogens including influenza, coronavirus and norovirus (via the commonly accepted surrogate feline calicivirus). The Company continues to advance alliances and commercial opportunities in the US, including with a previously announced, well-known sub-licensee in the US institutional market, which is continuing to prepare a market launch with the new product claims at the forefront of its marketing strategy.
Reported Earnings • Dec 13First half 2023 earnings released: UK£0.13 loss per share (vs UK£0 in 1H 2022)First half 2023 results: UK£0.13 loss per share (further deteriorated from UK£0 in 1H 2022). Revenue: UK£2.23m (down 30% from 1H 2022). Net loss: UK£579.0k (loss widened 391% from 1H 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 117 percentage points per year, which is a significant difference in performance.
공시 • Nov 22Byotrol plc Announces Management ChangesByotrol plc announced the following long-planned board changes. John Langlands, Non-Executive Chairman since February 2017, has notified the Board of his retirement from business and to step-down as Chairman and as a Director of Byotrol. John originally only intended to serve as Chairman of Byotrol for five years, but has remained slightly longer to guide the Company through this year's AGM. John will initially remain as a Non Executive Director to aid the leadership transition, but will then retire as a Director on 31 January 2023, having completed 6 years of service. David Traynor, Chief Executive Officer since October 2013 is moving to Executive Chairman, with immediate effect. In addition to his responsibilities as Chairman, David will now focus on securing and developing intellectual property agreements and commercial alliances for the Company. Vivan Pinto, currently Byotrol's Chief Growth Officer, and formerly VP and Area MD at Johnson and Johnson Consumer Health, is being promoted to Chief Executive Officer and joins the Board as an Executive Director with immediate effect. He will now assume formal responsibility for the day-to-day sales and operations of the Company, working closely with Chris Sedwell, Executive Director and Chief Financial Officer.
Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CFO & Director Chris Sedwell was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 20Full year 2022 earnings released: UK£0.003 loss per share (vs UK£0.002 profit in FY 2021)Full year 2022 results: UK£0.003 loss per share (down from UK£0.002 profit in FY 2021). Revenue: UK£6.33m (down 44% from FY 2021). Net loss: UK£1.35m (down 238% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.
Reported Earnings • Sep 01Full year 2022 earnings released: UK£0.003 loss per share (vs UK£0.002 profit in FY 2021)Full year 2022 results: UK£0.003 loss per share (down from UK£0.002 profit in FY 2021). Revenue: UK£6.33m (down 44% from FY 2021). Net loss: UK£1.35m (down 238% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.
공시 • Sep 01Byotrol plc, Annual General Meeting, Sep 22, 2022Byotrol plc, Annual General Meeting, Sep 22, 2022, at 10:00 Coordinated Universal Time.
공시 • Jul 29Byotrol plc announced that it has received £1 million in fundingByotrol plc announced a private placement of convertible loan notes for gross proceeds of £1,000,000 on July 28, 2022. The transaction included participation from new investors C Sedwell, Chief Financial Officer for £50,000, S Gogarty, Non-Executive Director for £100,000 and returning investors D Traynor, Chief Executive Officer for £50,000, V Pinto, Chief Growth Officer for £100,000, and T Francis, Non-Executive Director for £200,000. The loan notes have a term of five years, are senior in ranking, unsecured and convertible at investors' option into ordinary shares in the capital of the company at a price of £0.0325 (3.25 pence) per ordinary share, representing a 30% premium to the mid-price of the company's share price at close of business on 26 July 2022. The loan notes carry a coupon of 9% per annum, payable quarterly in arrears.
공시 • Jul 11Byotrol plc Provides Earnings Guidance for the Full Year Ended March 31, 2022Byotrol plc provided earnings guidance for the full year ended March 31, 2022. For the period, the company expected Sales of £6.3 million, comprising £5.2 million from product sales and £1.1 million from IP sales and royalties.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CFO & Director Chris Sedwell was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 21Full year 2021 earnings released: EPS UK£0.002 (vs UK£0.001 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£11.2m (up 85% from FY 2020). Net income: UK£979.0k (up 193% from FY 2020). Profit margin: 8.7% (up from 5.5% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
공시 • Apr 24Byotrol plc Provides Earnings Guidance for the Full Year Ended March 31, 2021Byotrol plc provided earnings guidance for the full year ended March 31, 2021. For the period, the company expected turnover to be in excess of £11 million compared to £6.1 million a year ago.
공시 • Feb 27Byotrol plc Announces That It Has Developed and Externally Validated A New Test for Determining Whether Cleaning and Sanitising ProductsByotrol plc announced that it has developed and externally validated a new test for determining whether cleaning and sanitising products have long-lasting efficacy against viruses in real-life use. This new test determines whether sanitising and cleaning products offer any long-lasting protection against COVID-19. Byotrol is now standing behind product efficacy claims supporting infection control products that offer 24-hour protection against viruses and bacteria in real-life conditions, where surfaces are frequently touched. The Company believes that this new test could help minimise the spread of the virus when used in conjunction with the cleaning and sanitising of shops, schools and offices when they reopen. The company has developed the new test in response to an increasing number of products claiming long-lasting efficacy against coronavirus, based on laboratory conditions which ignore the constant abrasion of surfaces in real-life environments (and which would then make many products ineffective). The company developed the industry standard test for long-lasting efficacy in real-life against bacteria and yeast in 2014 with the help of independent industry experts. The test, named PAS 2424:2014, was approved by the British Standards Institute (BSI) and is the only British standard to prove the efficacy of a disinfectant product over 24 hours. The PAS 2424:2014 test is currently being reviewed by the CEN Committee for approval as a new European EN test standard. This new test for viruses simulates 'real-life' conditions by creating frequent abrasions on surfaces after products have been applied, to replicate frequent touching of surfaces throughout the day. The surfaces are then tested to see whether the product is still present and killing viruses. The test is limited to 24 hours, to ensure that the result is attributed to the efficacy of the product, not the length of time the virus has been left to dry out on a surface, which could result in a false positive. The company plans to gain approval from the BSI again, to make this new test the British standard for proving the long-lasting efficacy of disinfectants against viruses. The application of this test could help businesses and consumers select products which are proven to be effective in a variety of public spaces where surfaces are frequently touched, genuinely promoting public health.
Reported Earnings • Dec 10First half 2021 earnings released: EPS UK£0.002The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: UK£6.67m (up 207% from 1H 2020). Net income: UK£1.01m (up UK£1.64m from 1H 2020). Profit margin: 15% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue.
공시 • Nov 14Byotrol plc Announces Retirement of Till Medinger from the BoardByotrol plc now confirm the formal retirement of Dr. Till Medinger from the Board.
Reported Earnings • Oct 14Full year earnings released - EPS €0.00077Over the last 12 months the company has reported total profits of UK£334.0k, down 5.6% from the prior year. Total revenue was UK£6.07m over the last 12 months, up 7.1% from the prior year. Profit margins were 5.5%, which is in line with last year.
Analyst Estimate Surprise Post Earnings • Oct 14Annual earnings released: Revenue beats expectationsAnnual revenue exceeded analyst estimates by 1.2% at UK£6.07m. Revenue is forecast to grow 89% over the next year, while the growth in Chemicals industry in Germany is expected to stay flat.